149 related articles for article (PubMed ID: 7579509)
1. Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases.
MacGrogan G; Bonichon F; de Mascarel I; Trojani M; Durand M; Avril A; Coindre JM
Breast Cancer Res Treat; 1995; 36(1):71-81. PubMed ID: 7579509
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
3. Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma.
Kourea HP; Koutras AK; Scopa CD; Marangos MN; Tzoracoeleftherakis E; Koukouras D; Kalofonos HP
Mol Pathol; 2003 Dec; 56(6):328-35. PubMed ID: 14645695
[TBL] [Abstract][Full Text] [Related]
4. p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer.
Göhring UJ; Bersch A; Becker M; Neuhaus W; Schöndorf T
J Clin Pathol; 2001 Nov; 54(11):866-70. PubMed ID: 11684722
[TBL] [Abstract][Full Text] [Related]
5. p53 protein and vimentin in invasive ductal NOS breast carcinoma--relationship with survival and sites of metastases.
Domagala W; Striker G; Szadowska A; Dukowicz A; Harezga B; Osborn M
Eur J Cancer; 1994; 30A(10):1527-34. PubMed ID: 7833113
[TBL] [Abstract][Full Text] [Related]
6. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.
MacGrogan G; Mauriac L; Durand M; Bonichon F; Trojani M; de Mascarel I; Coindre JM
Br J Cancer; 1996 Nov; 74(9):1458-65. PubMed ID: 8912545
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of cytosolic p53 protein in breast cancer.
Montero S; Guzmán C; Vargas C; Ballestín C; Cortés-Funes H; Colomer R
Tumour Biol; 2001; 22(5):337-44. PubMed ID: 11553865
[TBL] [Abstract][Full Text] [Related]
8. HER2 as a prognostic factor in breast cancer.
Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
[TBL] [Abstract][Full Text] [Related]
9. Cysteine proteinase inhibitor cystatin A in breast cancer.
Kuopio T; Kankaanranta A; Jalava P; Kronqvist P; Kotkansalo T; Weber E; Collan Y
Cancer Res; 1998 Feb; 58(3):432-6. PubMed ID: 9458085
[TBL] [Abstract][Full Text] [Related]
10. Histological grade in invasive ductal carcinoma of breast correlates with the proliferative activity evaluated by BrdU: an immunohistochemical study including correlations with p53, c-erbB-2 and estrogen receptor status.
Moriki T; Takahashi T; Hiroi M; Yamane T; Hara H
Pathol Int; 1996 Jun; 46(6):417-25. PubMed ID: 8869993
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases.
Soubeyran I; Wafflart J; Bonichon F; de Mascarel I; Trojani M; Durand M; Avril A; Coindre JM
Breast Cancer Res Treat; 1995 May; 34(2):119-28. PubMed ID: 7647329
[TBL] [Abstract][Full Text] [Related]
12. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer.
O'Malley FP; Saad Z; Kerkvliet N; Doig G; Stitt L; Ainsworth P; Hundal H; Chambers AF; Turnbull DI; Bramwell V
Hum Pathol; 1996 Sep; 27(9):955-63. PubMed ID: 8816892
[TBL] [Abstract][Full Text] [Related]
13. Breast carcinoma in women under the age of 50: Relationship between p53 immunostaining, tumour grade, and axillary lymph node status.
Pratap R; Shousha S
Breast Cancer Res Treat; 1998 May; 49(1):35-9. PubMed ID: 9694609
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of CSN6 protein expression and correlation with mutant-type P53 protein in breast cancer.
Wang W; Tang M; Zhang L; Xu X; Qi X; Yang Y; Jin F; Chen B
Jpn J Clin Oncol; 2013 Dec; 43(12):1170-6. PubMed ID: 24106298
[TBL] [Abstract][Full Text] [Related]
15. Invasive micropapillary carcinoma of the breast has a better long-term survival than invasive ductal carcinoma of the breast in spite of its aggressive clinical presentations: a comparison based on large population database and case-control analysis.
Chen H; Wu K; Wang M; Wang F; Zhang M; Zhang P
Cancer Med; 2017 Dec; 6(12):2775-2786. PubMed ID: 29072365
[TBL] [Abstract][Full Text] [Related]
16. Fibrotic focus in invasive ductal carcinoma of the breast: a histopathological prognostic parameter for tumor recurrence and tumor death within three years after the initial operation.
Hasebe T; Tsuda H; Tsubono Y; Imoto S; Mukai K
Jpn J Cancer Res; 1997 Jun; 88(6):590-9. PubMed ID: 9263537
[TBL] [Abstract][Full Text] [Related]
17. The relationship between expression of p53/Bcl-2 and histopathological criteria in breast invasive ductal carcinomas.
Gursan N; Karakök M; Sari I; Gursan MS
Int J Clin Pract; 2001 Nov; 55(9):589-90. PubMed ID: 11770353
[TBL] [Abstract][Full Text] [Related]
18. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical prognostic index for breast cancer in young women.
Guerra I; Algorta J; Díaz de Otazu R; Pelayo A; Fariña J
Mol Pathol; 2003 Dec; 56(6):323-7. PubMed ID: 14645694
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer.
Ioachim E; Tsanou E; Briasoulis E; Batsis Ch; Karavasilis V; Charchanti A; Pavlidis N; Agnantis NJ
Breast; 2003 Apr; 12(2):111-9. PubMed ID: 14659340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
